Compare KALA & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | HTCR |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.3M |
| IPO Year | 2017 | 2022 |
| Metric | KALA | HTCR |
|---|---|---|
| Price | $3.04 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 164.5K | 23.3K |
| Earning Date | 12-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | ★ 214.88% |
| EPS Growth | 67.39 | ★ 414.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,407,229.00 |
| Revenue This Year | N/A | $118.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.19 |
| 52 Week Low | $0.07 | $1.15 |
| 52 Week High | $191.00 | $10.43 |
| Indicator | KALA | HTCR |
|---|---|---|
| Relative Strength Index (RSI) | 77.25 | 45.35 |
| Support Level | $2.07 | $1.20 |
| Resistance Level | $3.71 | $1.88 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.38 | 0.00 |
| Stochastic Oscillator | 73.26 | 33.85 |
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.